Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
65.47%
Operating Margin
0.00%
Net Margin
16.87%
Efficiency Metrics
Revenue per Expense Ratio
1.30
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.75%
EPS
0.2900000000
Balance Sheet Analysis
Current Ratio
0.04
Cash Ratio
0.04
Working Capital
$-5.36B
Debt to Equity
3.15
Debt to Assets
74.81%
Equity Ratio
23.76%
Cash Flow Analysis
Operating Cash Flow Ratio
79.47%
Free Cash Flow Ratio
58.40%
CapEx to Revenue
21.08%
Dividends Paid
$214.29M
Stock Buybacks
$6.86M
Total Shareholder Returns
$221.15M
Cash Position Change
1.53%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 0.15%
Detailed Growth Metrics
Core Performance
Revenue
337.89%
Net Income
1,198.19%
EPS
869.23%
Operating Income
-100.00%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
127.56%
Operating Cash Flow
2.30%
Free Cash Flow
-14.25%
Balance Sheet Health
Assets
-2.84%
Debt
202.61%
Book Value per Share
-6.69%
Inventory
100.00%
Shareholder Returns
Dividends per Share
0.15%
Shares Outstanding
0.53%
Long Term Trends
3Y Revenue/Share
41.86%
5Y Revenue/Share
3.68%
3Y Dividend/Share
-10.67%
5Y Dividend/Share
-8.35%